新生血管性年龄相关性黄斑变性中的黄斑萎缩:比较雷珠单抗与阿柏西普的随机临床试验(RIVAL研究)
这项4期随机、部分设盲、多中心研究纳入278例新生血管性年龄相关性黄斑变性患者,比较雷珠单抗0.5mg与阿柏西普2.0mg按相同治疗并延长方案治疗24个月后黄斑萎缩的变化。结果显示两组黄斑萎缩面积平方根平均变化差异无统计学意义(+0.36mm vs +0.28mm,P=0.24),黄斑萎缩发生率增长及不良事件率相似。
要点
- 雷珠单抗组与阿柏西普组24个月黄斑萎缩面积平方根平均变化分别为+0.36mm和+0.28mm,差异无统计学意义(P=0.24)。
- 两组黄斑萎缩发生率从基线至24个月分别由7%增至37%和由6%增至32%。
- 两组年均注射次数相似(9.6次 vs 9.5次),24个月BCVA平均变化分别为+6.6字母和+4.6字母(P=0.15)。
核心结论
- 在采用相同治疗并延长方案的nAMD患者中,雷珠单抗与阿柏西普治疗24个月黄斑萎缩的发生率或增长速率无显著差异。
研究设计与样本
- 4期随机、部分设盲、多中心研究,纳入278例50岁及以上活动性、未治疗的新生血管性年龄相关性黄斑变性伴中心凹下脉络膜新生血管患者,基线最佳矫正视力≥23个logMAR字母。
- 患者按1:1随机接受玻璃体腔内注射雷珠单抗0.5mg(n=141)或阿柏西普2.0mg(n=137),初始3次每月注射后按相同读片中心指导的治疗并延长方案治疗。
主要发现
- 黄斑萎缩面积平方根从基线至24个月平均变化:雷珠单抗组+0.36mm(95%CI 0.27-0.45mm),阿柏西普组+0.28mm(95%CI 0.19-0.37mm),治疗差异+0.08mm(95%CI -0.05至0.21mm;P=0.24)。
- 黄斑萎缩患者比例从基线至24个月:雷珠单抗组由7%(10/141)增至37%(43/117),阿柏西普组由6%(8/137)增至32%(35/108)。
- 年均注射次数:雷珠单抗组9.6次(95%CI 9.2-10.0),阿柏西普组9.5次(95%CI 9.1-9.9)。
- 最佳矫正视力从基线至24个月平均变化:雷珠单抗组+6.6字母(95%CI 4.7-8.5字母),阿柏西普组+4.6字母(95%CI 2.7-6.6字母)(P=0.15)。
- 两组不良事件发生率相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate differences in the development of macular atrophy (MA) over 24 months between treat-and-extend (T&E) ranibizumab and aflibercept in patients with neovascular age-related macular degeneration (nAMD). DESIGN: A phase 4 randomized, partially masked, multicenter study. PARTICIPANTS: Individuals 50 years of age or older diagnosed with active, treatment-naïve subfoveal choroidal neovascularization secondary to nAMD with baseline best-corrected visual acuity (BCVA) of 23 logarithm of minimum angle of resolution letters or more. METHODS: Patients were randomized 1:1 to receive either intravitreal injections of ranibizumab 0.5 mg or aflibercept 2.0 mg and were treated according to the same reading center-guided T&E regimen after 3 initial monthly injections. MAIN OUTCOME MEASURES: The primary outcome was mean change in square root area of MA from baseline to month 24. Key secondary outcomes included number of injections and mean change in BCVA from baseline to months 12 and 24. RESULTS: Two hundred seventy-eight patients were included in the analysis (ranibizumab 0.5 mg, n = 141; aflibercept 2.0 mg, n = 137). Mean change in square root area of MA from baseline to month 24 was +0.36 mm (95% confidence interval [CI], 0.27-0.45 mm) for ranibizumab and +0.28 mm (95% CI, 0.19-0.37 mm) for aflibercept (treatment difference, +0.08 mm [95% CI, -0.05 to 0.21 mm]; P = 0.24). The proportion of patients with MA increased from 7% (10/141) to 37% (43/117) for ranibizumab and from 6% (8/137) to 32% (35/108) for aflibercept from baseline to month 24. The average number of injections received per year was similar between both groups: 9.6 (95% CI, 9.2-10.0) for ranibizumab and 9.5 (95% CI, 9.1-9.9) for aflibercept. The mean change in BCVA from baseline to month 24 was +6.6 letters (95% CI,4.7-8.5 letters) for the ranibizumab group and +4.6 letters (95% CI, 2.7-6.6 letters) for the aflibercept group ( P = 0.15). Rates of adverse events (AEs) were similar between both groups. CONCLUSIONS: No significant differences in the rate of development or growth of MA over 24 months were observed between ranibizumab and aflibercept in nAMD patients treated using an identical T&E regimen.
引用
- Gillies MC, Hunyor AP, Arnold JJ, et al. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study). Ophthalmology. 2019. PMID: 31619357. doi:10.1016/j.ophtha.2019.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。